武汉友芝友生物制药股份有限公司(香港联交所代码:02496.HK,下称 “友芝友生物”)宣布,核心管线产品 M701 治疗恶性腹水的 II 期临床研究结果,正式发表于国际知名学术期刊《Experimental Hematology & Oncology(EHO)》,标志着该创新疗法的临床价值获国际学术界权威认可。临床研究作为晚期上皮性癌症的难治性并发症,恶性腹水临床缺乏有效治疗手段,传统穿刺引流...
Source Link武汉友芝友生物制药股份有限公司(香港联交所代码:02496.HK,下称 “友芝友生物”)宣布,核心管线产品 M701 治疗恶性腹水的 II 期临床研究结果,正式发表于国际知名学术期刊《Experimental Hematology & Oncology(EHO)》,标志着该创新疗法的临床价值获国际学术界权威认可。临床研究作为晚期上皮性癌症的难治性并发症,恶性腹水临床缺乏有效治疗手段,传统穿刺引流...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.